C224 - Controversies in Multiple Sclerosis Therapy

Event Time: Friday April 28, 2017 7:00 am to 9:00 am
Topic(s): MS and CNS Inflammatory Disease
Director(s): Riley Bove MD
Description: Disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) are considered to be most effective when started early in the course of the disease. Should patients with clinically and radiologically isolated syndromes be started on disease modifying therapy? Should MS patients with stable disease be trialed off of MS disease-modifying therapy and if so, under what circumstances? Should all MS patients with seropositivity for JC virus antibody discontinue natalizumab treatment? Should all patients with MS be treated with vitamin D supplementation? Definitive evidence-based criteria may remain uncertain, but faculty will discuss and debate the merits, the available evidence, and their own clinical experience that can assist participants in making these important treatment decisions.
Completion Message: Participants should be able to describe and discuss the relative pros and cons of a number of controversies in MS evaluation and therapy.
CME Credits: 2
Core Competencies: Interpersonal and Communication Skills, Medical Knowledge, Patient Care, Practice-Based Learning and Improvement

Ready to register for the 2018 AAN Annual Meeting?

Register Now

Related Courses